BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vertex Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Vertex Pharmaceuticals's drugs ru
 n\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06696443-8794@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20270125
DTEND;VALUE=DATE:20270126
SUMMARY:Journavx (Suzetrigine): Phase 3 readout est. (NCT06696443)
DESCRIPTION:Journavx (Suzetrigine)\, phase 3\, Diabetic Peripheral Neuropat
 hic Pain.\nStudy: Evaluation of the Long-term Safety and Effectiveness of 
 Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropa
 thy (DPN)\nEstimated primary completion: 25 January 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/suzetrigine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06696443
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06185764-10843@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:VX-670: Phase 1/2 readout est. (NCT06185764)
DESCRIPTION:VX-670\, phase 1/2\, Myotonic Dystrophy Type 1.\nStudy: A Phase
  1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
 \nEstimated primary completion: 2 February 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/vx-670#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06185764
URL:https://assetmemo.bio/drug/vx-670#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06619860-8820@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20270325
DTEND;VALUE=DATE:20270326
SUMMARY:VX-993: Phase 2 readout est. (NCT06619860)
DESCRIPTION:VX-993\, phase 2\, Diabetic Peripheral Neuropathic Pain.\nStudy
 : Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Dia
 betic Peripheral Neuropathy\nEstimated primary completion: 25 March 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/vx-993#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06619860
URL:https://assetmemo.bio/drug/vx-993#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05331183-10838@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:Trikafta (Elexacaftor / tezacaftor / ivacaftor): Phase 3 readout es
 t. (NCT05331183)
DESCRIPTION:Trikafta (Elexacaftor / tezacaftor / ivacaftor)\, phase 3\, Cys
 tic Fibrosis.\nStudy: Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (
 ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del\nEs
 timated primary completion: 6 April 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/elexacaftor-tezacaftor-ivacaftor#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05331183
URL:https://assetmemo.bio/drug/elexacaftor-tezacaftor-ivacaftor#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07231419-8794@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:Journavx (Suzetrigine): Phase 3 readout est. (NCT07231419)
DESCRIPTION:Journavx (Suzetrigine)\, phase 3\, Diabetic Peripheral Neuropat
 hic Pain.\nStudy: Evaluation of Efficacy and Safety of Suzetrigine (SUZ) f
 or Pain Associated With Diabetic Peripheral Neuropathy\nEstimated primary 
 completion: 6 April 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/suzetrigine#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07231419
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06628908-8794@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Journavx (Suzetrigine): Phase 3 readout est. (NCT06628908)
DESCRIPTION:Journavx (Suzetrigine)\, phase 3\, Diabetic Peripheral Neuropat
 hic Pain.\nStudy: Evaluation of Efficacy and Safety of Suzetrigine for Pai
 n Associated With Diabetic Peripheral Neuropathy\nEstimated primary comple
 tion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/su
 zetrigine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06628908
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05329649-10277@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20270606
DTEND;VALUE=DATE:20270607
SUMMARY:Exagamglogene autotemcel (Casgevy): Phase 3 readout est. (NCT053296
 49)
DESCRIPTION:Exagamglogene autotemcel (Casgevy)\, phase 3\, Sickle Cell Dise
 ase.\nStudy: Evaluation of Safety and Efficacy of CTX001 in Pediatric Part
 icipants With Severe Sickle Cell Disease (SCD)\nEstimated primary completi
 on: 6 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/exag
 amglogene-autotemcel-casgevy#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05329649
URL:https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05477563-10277@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20270609
DTEND;VALUE=DATE:20270610
SUMMARY:Exagamglogene autotemcel (Casgevy): Phase 3 readout est. (NCT054775
 63)
DESCRIPTION:Exagamglogene autotemcel (Casgevy)\, phase 3\, Sickle Cell Dise
 ase.\nStudy: Evaluation of Efficacy and Safety of a Single Dose of CTX001 
 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickl
 e Cell Disease\nEstimated primary completion: 9 June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0547756
 3
URL:https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07161037-10842@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:VX-407: Phase 2 readout est. (NCT07161037)
DESCRIPTION:VX-407\, phase 2\, Autosomal Dominant Polycystic Kidney Disease
 .\nStudy: Phase 2a Study of VX-407 in Participants With ADPKD Who Have a S
 ubset of PKD1 Gene Variants (AGLOW)\nEstimated primary completion: 22 July
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/vx-407#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07161037
URL:https://assetmemo.bio/drug/vx-407#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06460506-10838@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Trikafta (Elexacaftor / tezacaftor / ivacaftor): Phase 3 readout es
 t. (NCT06460506)
DESCRIPTION:Trikafta (Elexacaftor / tezacaftor / ivacaftor)\, phase 3\, Cys
 tic Fibrosis.\nStudy: Evaluation of Long-term Safety and Efficacy of ELX/T
 EZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older\nEstimat
 ed primary completion: 30 September 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/elexacaftor-tezacaftor-ivacaftor#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06460506
URL:https://assetmemo.bio/drug/elexacaftor-tezacaftor-ivacaftor#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05356195-10277@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20271114
DTEND;VALUE=DATE:20271115
SUMMARY:Exagamglogene autotemcel (Casgevy): Phase 3 readout est. (NCT053561
 95)
DESCRIPTION:Exagamglogene autotemcel (Casgevy)\, phase 3.\nStudy: Evaluatio
 n of Safety and Efficacy of CTX001 in Pediatric Participants With Transfus
 ion-Dependent β-Thalassemia (TDT)\nEstimated primary completion: 14 Novem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/exagamgloge
 ne-autotemcel-casgevy#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05356195
URL:https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890909-10841@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20271212
DTEND;VALUE=DATE:20271213
SUMMARY:Povetacicept: Phase 3 readout est. (NCT07890909)
DESCRIPTION:Povetacicept\, phase 3\, IgA Nephropathy.\nStudy: A Phase 3b St
 udy of Participant Experience on Povetacicept Administered Via Autoinjecto
 r as Compared to Sibeprenlimab Administered Via Prefilled Syringe\nEstimat
 ed primary completion: 12 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/povetacicept#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07890909
URL:https://assetmemo.bio/drug/povetacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04786262-3443@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Zimislecel: Phase 3 readout est. (NCT04786262)
DESCRIPTION:Zimislecel\, phase 3\, Type 1 Diabetes.\nStudy: A Safety\, Tole
 rability\, and Efficacy Study of VX-880 and VX-017 in Participants With Ty
 pe 1 Diabetes\nEstimated primary completion: 31 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/zimislecel#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04786262
URL:https://assetmemo.bio/drug/zimislecel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06564142-10841@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Povetacicept: Phase 3 readout est. (NCT06564142)
DESCRIPTION:Povetacicept\, phase 3\, IgA Nephropathy.\nStudy: Evaluation of
  Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgA
 N)\nEstimated primary completion: 30 January 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/povetacicept#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06564142
URL:https://assetmemo.bio/drug/povetacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05312879-913@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20280602
DTEND;VALUE=DATE:20280603
SUMMARY:Inaxaplin: Phase 2/3 readout est. (NCT05312879)
DESCRIPTION:Inaxaplin\, phase 2/3\, Chronic Kidney Disease.\nStudy: Phase 2
 /3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1
 -Mediated Proteinuric Kidney Disease\nEstimated primary completion: 2 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/inaxaplin#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05312879
URL:https://assetmemo.bio/drug/inaxaplin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06926621-10843@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20290130
DTEND;VALUE=DATE:20290131
SUMMARY:VX-670: Phase 2 readout est. (NCT06926621)
DESCRIPTION:VX-670\, phase 2\, Myotonic Dystrophy Type 1.\nStudy: A Study o
 f Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dy
 strophy Type I\nEstimated primary completion: 30 January 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/vx-670#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06926621
URL:https://assetmemo.bio/drug/vx-670#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07501702-10841@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20290302
DTEND;VALUE=DATE:20290303
SUMMARY:Povetacicept: Phase 2 readout est. (NCT07501702)
DESCRIPTION:Povetacicept\, phase 2\, Myasthenia Gravis.\nStudy: A Phase 2 S
 tudy to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
 \nEstimated primary completion: 2 March 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/povetacicept#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07501702
URL:https://assetmemo.bio/drug/povetacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07204275-10841@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20290627
DTEND;VALUE=DATE:20290628
SUMMARY:Povetacicept: Phase 2/3 readout est. (NCT07204275)
DESCRIPTION:Povetacicept\, phase 2/3\, Primary Membranous Nephropathy.\nStu
 dy: Evaluation of Efficacy\, Safety\, and Tolerability of Povetacicept in 
 Participants With Primary Membranous Nephropathy (pMN)\nEstimated primary 
 completion: 27 June 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/povetacicept#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07204275
URL:https://assetmemo.bio/drug/povetacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05844449-10837@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20290730
DTEND;VALUE=DATE:20290731
SUMMARY:Alyftrek (Vanzacaftor / tezacaftor / deutivacaftor): Phase 3 readou
 t est. (NCT05844449)
DESCRIPTION:Alyftrek (Vanzacaftor / tezacaftor / deutivacaftor)\, phase 3\,
  Cystic Fibrosis.\nStudy: Evaluation of Long-Term Safety and Efficacy of V
 anzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year
  of Age and Older\nEstimated primary completion: 30 July 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/vanzacaftor-tezacaftor-deutivaca
 ftor#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05844449
URL:https://assetmemo.bio/drug/vanzacaftor-tezacaftor-deutivacaftor#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07807995-10841@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20291228
DTEND;VALUE=DATE:20291229
SUMMARY:Povetacicept: Phase 3 readout est. (NCT07807995)
DESCRIPTION:Povetacicept\, phase 3\, IgA Nephropathy.\nStudy: A Phase 3 Ope
 n-Label Study of Long-term Treatment With Povetacicept in Adults With Immu
 noglobulin A Nephropathy\nEstimated primary completion: 28 December 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/povetacicept#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07807995
URL:https://assetmemo.bio/drug/povetacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05422222-10837@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Alyftrek (Vanzacaftor / tezacaftor / deutivacaftor): Phase 3 readou
 t est. (NCT05422222)
DESCRIPTION:Alyftrek (Vanzacaftor / tezacaftor / deutivacaftor)\, phase 3\,
  Cystic Fibrosis.\nStudy: Evaluation of VX-121/Tezacaftor/Deutivacaftor in
  Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age\nEstimated pr
 imary completion: 30 June 2030. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/vanzacaftor-tezacaftor-deutivacaftor#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05422222
URL:https://assetmemo.bio/drug/vanzacaftor-tezacaftor-deutivacaftor#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04208529-10277@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20390930
DTEND;VALUE=DATE:20391001
SUMMARY:Exagamglogene autotemcel (Casgevy): Phase 3 readout est. (NCT042085
 29)
DESCRIPTION:Exagamglogene autotemcel (Casgevy)\, phase 3\, Sickle Cell Dise
 ase.\nStudy: A Long-term Follow-up Study in Participants Who Received CTX0
 01\nEstimated primary completion: 30 September 2039. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04208529
URL:https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
